umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Anti-Mullerian hormone and endometrial cancer: a multi-cohort study
Show others and affiliations
2017 (English)In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 117, no 9, p. 1412-1418Article in journal (Refereed) Published
Abstract [en]

Background: The Mullerian ducts are the embryological precursors of the female reproductive tract, including the uterus; anti-Mullerian hormone (AMH) has a key role in the regulation of foetal sexual differentiation. Anti-Mullerian hormone inhibits endometrial tumour growth in experimental models by stimulating apoptosis and cell cycle arrest. To date, there are no prospective epidemiologic data on circulating AMH and endometrial cancer risk. Methods: We investigated this association among women premenopausal at blood collection in a multicohort study including participants from eight studies located in the United States, Europe, and China. We identified 329 endometrial cancer cases and 339 matched controls. AntiMullerian hormone concentrations in blood were quantified using an enzyme-linked immunosorbent assay. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) across tertiles and for a doubling of AMH concentrations (ORlog2). Subgroup analyses were performed by ages at blood donation and diagnosis, oral contraceptive use, and tumour characteristics. Results: Anti-Mullerian hormone was not associated with the risk of endometrial cancer overall (ORlog(2): 1.07 (0.99-1.17)), or with any of the examined subgroups. Conclusions: Although experimental models implicate AMH in endometrial cancer growth inhibition, our findings do not support a role for circulating AMH in the aetiology of endometrial cancer.

Place, publisher, year, edition, pages
Nature Publishing Group, 2017. Vol. 117, no 9, p. 1412-1418
Keywords [en]
endometrial cancer, anti-Mullerian hormone, Mullerian inhibiting substance, multicohort study
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-141826DOI: 10.1038/bjc.2017.299ISI: 000413527300019PubMedID: 28873086OAI: oai:DiVA.org:umu-141826DiVA, id: diva2:1160224
Available from: 2017-11-24 Created: 2017-11-24 Last updated: 2018-06-09Bibliographically approved

Open Access in DiVA

fulltext(322 kB)0 downloads
File information
File name FULLTEXT01.pdfFile size 322 kBChecksum SHA-512
ca7f237cd74fe1aac342a7f82997aa10500136c7f452b93382d782a4e4a3081c7394ea0a7f09723ee1eeaaa9acc49b32e757e2b930c6c391bacede825ad1b44e
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Idahl, AnnikaLundin, EvaWeiderpass, Elisabete

Search in DiVA

By author/editor
Idahl, AnnikaLundin, EvaWeiderpass, Elisabete
By organisation
Obstetrics and GynecologyDepartment of Medical Biosciences
In the same journal
British Journal of Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 42 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf